Core Insights - The company reported a revenue of 299.1 billion RMB for Q3 2025, representing a year-on-year growth of 14.9%, while the net profit attributable to ordinary shareholders decreased by 120.8% to 5.3 billion RMB [1][2]. Retail Performance - JD Retail achieved a revenue of 250.6 billion RMB in Q3 2025, up from 225.0 billion RMB in Q3 2024, marking an increase of 11.4% [2][9]. - The company launched five strategic initiatives to expand JD Supermarket's user base over the next three years, focusing on product differentiation and operational efficiency [3]. Logistics Development - JD Logistics reported a revenue of 55.1 billion RMB in Q3 2025, a significant increase of 24.1% compared to the previous year [2][9]. - The company opened a new high-standard warehouse in Dubai, marking its ninth overseas warehouse in the Middle East, enhancing its logistics capabilities in the region [4]. New Business Segment - The new business segment, which includes JD Delivery, saw a revenue increase of 213.7% year-on-year, recovering from a previous decline of 25.7% [6][8]. - Despite the growth in revenue, the new business segment still faced significant operational losses, amounting to 157.36 billion RMB in Q3 2025 [6][7]. Health Sector Initiatives - JD Health signed strategic cooperation agreements with major pharmaceutical companies, launching several new drugs on its platform [5]. - The company is developing an AI-driven health management system, aiming to cover various health monitoring areas beyond just blood sugar management [5]. Share Buyback and Market Performance - The company announced a share buyback plan, repurchasing approximately 80.9 million Class A ordinary shares for about 1.5 billion USD, with a remaining buyback amount of 3.5 billion USD [11]. - As of the report date, JD's stock was trading at 31.25 USD per share, reflecting a decline of 1.14% [11].

JD Health International Inc. 京東健康股份有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6618（港幣櫃台）及86618（人民幣櫃台）） 內幕消息 2025 年第三季度之未經審計最新資料 本公告乃由京东健康股份有限公司（「本公司」或「京東健康」，連同其子公司及關聯併表 實體統稱「本集團」）根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規 則」）第13.09條及香港法例第571章證券及期貨條例第XIVA部項下的內幕消息條文（定義 見上市規則）而刊發。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責任。 業務最新資料 2025年第三季度，京東健康與禮來、信達生物、衛材中國及拜耳中國等知名藥企簽署戰 略合作協定。衛材藥企旗下原研新藥達衛可® （萊博雷生片）、恒瑞旗下乾眼症新藥恆沁® （全氟己基辛烷滴眼液）、拜耳旗下達喜® 乳果糖等新藥也選擇在京東健康全網首發，繼 續鞏固京東健康「新特藥全網首發第一站」心智。除藥 ...